Abstract
Cardiac arrhythmias range from the fast-beating tachyarrhythmias–which include atrial fibrillation, ventricular tachycardia, and fibrillation and the slow-beating bradyarrhythmias–which include sick sinus syndrome and heart blocks. Compounded with other co-existent cardiovascular risk factors, these arrhythmias can result in enhanced mortality rates—including sudden cardiac deaths. Aberrations in cardiac impulse formation or conduction can result in arrhythmias and the antiarrhythmic drugs exert their action by optimally tilting these imbalances. The chapter includes in-depth discussion on the various antiarrhythmic drugs—classified based on both the classical Singh-Vaughan Williams system (1970) and the modernized system of classification proposed by Lei et al. (Circulation 138:1879–96, 2018); the former includes four classes (Class 1, 2, 3, and 4) and the latter includes additional four classes (Class 0, 5, 6, and 7). The clinical application with the guiding principles for antiarrhythmic drug use is also elucidated.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Bibliography
Abdul-Aziz AA, Altawil M, Lyon A, MacEachern M, Richardson CR, Rubenfire M et al (2018) Lifestyle therapy for the management of atrial fibrillation. Am J Cardiol 121:1112–1117
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB et al (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm 15:e190–e252
Aro AL, Chugh SS (2018) Epidemiology and global burden of arrhythmias. In: Camm AJ, Lüscher TF, Maurer G, Serruys PW (eds) ESC CardioMed, 3rd edn. Oxford University Press, Oxford
Barrett KE, Barman SM, Brooks HL, Yuan JX-J (2019) Origin of the heartbeat & the electrical activity of the heart. In: Ganong’s review of medical physiology, 26th edn. McGraw-Hill Education, New York
Bashore TM, Granger CB, Jackson KP, Patel MR (2019) Heart disease. In: Papadakis MA, Mcphee SJ (eds) Current medical diagnosis & treatment, 58th edn. McGraw-Hill Education, New York, pp 334–450
Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A et al (2019) European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Eur Secur 21:7–8
Dan G-A, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F et al (2018) Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Eur Secur 20:731–732
Harvey RD, Grant AO (2018) Agents used in cardiac arrhythmias. In: Katzung BG (ed) Basic & clinical pharmacology, 14th edn. McGraw-Hill Education, New York, pp 228–253
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation 130:2071–2104
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 74:104–132
JCS Joint Working Group (2013) Guidelines for non-pharmacotherapy of cardiac arrhythmias (JCS 2011). Circ J 77:249–274
King GS, McGuigan JJ (2019) Antiarrhythmic medications. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). http://www.ncbi.nlm.nih.gov/books/NBK482322/. Accessed 25 Jul 2019
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962
Knollmann BC, Roden DM (2018) Antiarrhythmic drugs. In: Brunton LL, Hilal-Dandan R, Knollmann BC (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 13th edn. McGraw-Hill Education, New York, pp 547–572
Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR et al (2019) 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines, and the Heart Rhythm Society. J Am Coll Cardiol 74:932–987. https://doi.org/10.1016/j.jacc.2018.10.043
Lei M, Wu L, Terrar DA, Huang CL-H (2018) Modernized classification of cardiac antiarrhythmic drugs. Circulation 138:1879–1896
Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ et al (2016) 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Circulation 133:e506–e574
Perna F, Leo M (2012) Epidemiology, classification and description of cardiac arrhythmias. In: Fioranelli M, Frajese G (eds) Sports cardiology: from diagnosis to clinical management. Springer-Verlag, Milano, pp 155–177
Task Force of the Working Group on Arrhythmias, the European Society of Cardiology (1991) The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 84:1831–1851
Van Gelder IC, Rienstra M, Crijns HJGM, Olshansky B (2016) Rate control in atrial fibrillation. Lancet 388:818–828
Waks JW, Zimetbaum P (2017) Antiarrhythmic drug therapy for rhythm control in atrial fibrillation. J Cardiovasc Pharmacol Ther 22:3–19
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Raj, G.M. (2021). Drugs Used in Cardiac Arrhythmias. In: Paul, A., Anandabaskar, N., Mathaiyan, J., Raj, G.M. (eds) Introduction to Basics of Pharmacology and Toxicology. Springer, Singapore. https://doi.org/10.1007/978-981-33-6009-9_27
Download citation
DOI: https://doi.org/10.1007/978-981-33-6009-9_27
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-33-6008-2
Online ISBN: 978-981-33-6009-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)